S. Kobak, "Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma," CURRENT DRUG SAFETY , vol.14, no.3, pp.225-229, 2019
Kobak, S. 2019. Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma. CURRENT DRUG SAFETY , vol.14, no.3 , 225-229.
Kobak, S., (2019). Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma. CURRENT DRUG SAFETY , vol.14, no.3, 225-229.
Kobak, Senol. "Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma," CURRENT DRUG SAFETY , vol.14, no.3, 225-229, 2019
Kobak, Senol. "Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma." CURRENT DRUG SAFETY , vol.14, no.3, pp.225-229, 2019
Kobak, S. (2019) . "Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma." CURRENT DRUG SAFETY , vol.14, no.3, pp.225-229.
@article{article, author={Senol Kobak}, title={Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma}, journal={CURRENT DRUG SAFETY}, year=2019, pages={225-229} }